September 22, 2017
News Home
Global News
Product Exhibition
Company Directory
China Medical Device Industry Yearbook - 2017  (the Fourth Edition)

China Market for Color Ultrasound Equipment

Guided Therapeutics Enters into LuViva® Advanced Cervical Scan Manufacturing and License Agreement for China
  Guided Therapeutics, Inc.   January 25, 2017

Deal includes equity investment in Guided Therapeutics and commitment to fund all manufacturing start up, regulatory and distribution costs in China

NORCROSS, Ga. -- Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has reached agreement with Shandong Yaohua Medical Instrument Corporation in China for exclusive distribution, sales and manufacturing rights of the LuViva® Advanced Cervical Scan for China, Taiwan, Hong Kong and Macau.

In addition to a previous payment of $50,000 made by Shandong Yaohua, the terms of the license agreement include a licensing fee by Shandong Yaohua of $1,000,000, the purchase of a minimum of ten LuViva® Advance Cervical Scan devices in 2017 and royalties for disposables based on minimum orders once Chinese Food and Drug Administration (CFDA) approval is obtained. To further align the strategic interests of the parties, Guided Therapeutics has agreed to issue $1,000,000 in shares of its common stock to Shandong Yaohua.

Shandong Yaohua will conduct the necessary clinical trials and apply to the CFDA for approval to market LuViva in China. Once approved, Shandong Yaohua will provide for the distribution and sale of LuViva within China with its established distribution and sales network.

China is potentially the world’s largest market for cervical cancer screening with over 390 million women in the recommended ages for screening. The incidence of cervical cancer in China is currently the highest in the world and increasing. Increased screening for cervical cancer is key to mitigating the losses associated with this disease.

Under the terms of the agreement, Shandong Yaohua will establish manufacturing lines for LuViva within its existing medical device manufacturing facilities, which will enable Shandong Yaohua to supply Guided Therapeutics with LuViva products. With increased volume of production, advanced manufacturing processes and competitive labor rates, the Company expects that Shandong Yaohua will be able to lower the costs for the LuViva device and disposables for the global market. Worldwide, the market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020. There are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer worldwide.

“We are pleased to be partnering with Shandong Yaohua to bring LuViva to China and improve early detection in a market where cervical cancer, often found too late, is the second leading killer among women’s cancers,” said Gene Cartwright, CEO and President of Guided Therapeutics. “The agreement also opens up the possibility to bring efficiencies to our manufacturing processes as well as opening up additional markets in East Asia.”

“LuViva is the ideal product to address this critical women’s health concern, which is a national priority for eradication in China,” said Li Yaohua, Chairman of Shandong Yaohua. “The combination of early detection and immediate results makes the LuViva appealing to the healthcare professional as well as the patient and her family.”

The Company currently anticipates interim device and disposable sales for clinical study and demonstration purposes. In Hong Kong, the Company believes the time to commercial sales is quicker, with device registration, rather than approval required.

About Shandong Yaohua Medical Instrument Corporation

Shandong Yaohua Medical Instrument Corporation, traded on the Chinese National Equities Exchange and Quotations as 833141, is the maker and distributor of medical devices and disposables for urine analysis, urine test strips, vacuum blood collection tubes and other medical products. They manufacture, distribute and sell to the domestic market in China, the Middle East and Eastern Asia. Shandong Yaohua Medical Instrument Corporation is located in the high-tech development zone of Shandong Province, where it owns an 86,600 square meter production facility with 20,000 square meters of floor space dedicated to the high tech manufacture of medical devices. Total revenue in 2015 for all Shandong Yaohua holdings was approximately 87 million RMB ($12.7 million USD).

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing. LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit:

The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.


Guided Therapeutics
Bill Wells, 770-242-8723

Market Intelligence and Business Development Solutions to the Chinese MedTech Industry
Latest News


Copyright China MedTech Marketing Solutions Inc. (CMTM)